NoviThera has initiated the first efficacy animal studies

Core Insights - NoviThera ApS has initiated its first efficacy studies on animals for a novel treatment targeting psoriasis, a chronic inflammatory skin condition [1][9] - The company is focusing on a specific endogenous polypeptide that is hypothesized to be responsible for the pathology of psoriasis, with the aim of reducing or removing it to cure and prevent disease progression [3][10] Company Overview - NoviThera is a majority-owned subsidiary of Nordicus Partners Corporation, which specializes in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market [1][11] - The mission of NoviThera is to research and develop a unique monoclonal antibody as an innovative therapy for psoriasis [10] Research and Development Activities - Two preclinical mouse studies are currently underway to document biological proof of concept for the treatment [8] - The first study involves intradermal injections at the plaque site, treating animals that develop psoriasis with a proprietary monoclonal antibody [8] - The second study is focused on developing a humanized genetic mouse capable of producing the polypeptide, which is unique to humans, to facilitate further animal studies [9] Mechanism of Action - The polypeptide in question is a cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial and immunomodulatory properties [4] - It is involved in the regulation of the immune system and has a pro-inflammatory role in psoriasis, exacerbating inflammation by promoting immune cell activation [5] - The polypeptide binds to self-DNA and self-RNA from damaged keratinocytes, activating plasmacytoid dendritic cells and leading to the production of type I interferons [6][7] Future Plans - After completing the current studies, NoviThera plans to conduct toxicity studies in 2027 and initiate patient testing in 2028 [9]